ARMP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q3

FY2025Q4

1.38M

+42.86%

1.38M

-53.58%

1.48M

+19.84%

Estimates Revision

The market is revising No Change the revenue expectations for Armata Pharmaceuticals, Inc. (ARMP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 145.79%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+145.79%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

JonesResearch

Debanjana Chatterjee

Buy

initiated

$15

2026-01-05

New

Reason

JonesResearch

Debanjana Chatterjee

Price Target

$15

2026-01-05

New

initiated

Buy

Reason

JonesResearch analyst Debanjana Chatterjee initiated coverage of Armata Pharmaceuticals with a Buy rating and $15 price target. What differentiates Armata from other companies developing clinical-stage phage therapies is the combination of a proprietary off-the-shelf phage platform and in-house cGMP manufacturing that can consistently produce high-purity, high-titer, clinical-grade phage cocktails, the analyst tells investors. Armata is developing AP-SA02 and AP-PA02 against difficult-to-treat Staph. aureus bacteremia and Pseudomonas aeruginosa infections, respectively, the analyst noted.

H.C. Wainwright

Buy

maintain

2025-10-22

Reason

H.C. Wainwright

Price Target

2025-10-22

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals after the company shared new data from the recently completed Phase 2a diSArm study in a late-breaking oral presentation at IDWeek 2025. These new in vitro data providing strong evidence for the efficacy of its core therapeutic strategy for AP-SA02, along with the broader dataset, support advancement into a pivotal Phase 3 trial set to begin in 2026, the analyst tells investors.

H.C. Wainwright

Buy

maintain

$7 -> $9

2025-05-19

Reason

H.C. Wainwright

Price Target

$7 -> $9

2025-05-19

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Armata Pharmaceuticals to $9 from $7 and keeps a Buy rating on the shares. The company this morning announced a "very big clinical win as well a defining moment for bacteriophage therapy," the analyst tells investors in a research note. The firm says the Phase 1b/2a study, diSArm, has met all primary endpoints. The study and highlights, beyond the "strong" clinical responses, that from the petri dish to the patient, AP-SA02 shows the ability to home to site of infections, kill, amplify, and re-home to kill some more, before being cleared by the liver, contends H.C. Wainwright.

Valuation Metrics

The current forward P/E ratio for Armata Pharmaceuticals Inc (ARMP.A) is -4.26, compared to its 5-year average forward P/E of -2.97. For a more detailed relative valuation and DCF analysis to assess Armata Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.97

Current PE

-4.26

Overvalued PE

-1.41

Undervalued PE

-4.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.48

Current EV/EBITDA

-12.92

Overvalued EV/EBITDA

-0.85

Undervalued EV/EBITDA

-6.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

22.84

Current PS

45.06

Overvalued PS

33.80

Undervalued PS

11.88

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ARMP News & Events

Events Timeline

No data

News

9.5

2025-11-07NASDAQ.COM

Coherus Oncology (CHRS) Posts Q3 Loss and Falls Short of Revenue Projections

9.0

2025-10-23NASDAQ.COM

Armata Pharmaceuticals (ARMP) Soars 103.2%: Could This Signal More Upside Ahead?

9.0

2025-10-22TipRanks

Reasons Behind the 300% Surge in Armata Pharmaceuticals Stock (ARMP) Today

People Also Watch

Frequently Asked Questions

What is Armata Pharmaceuticals Inc (ARMP) stock price today?

The current price of ARMP is 7.89 USD — it has increased 18.11 % in the last trading day.

What is Armata Pharmaceuticals Inc (ARMP)'s business?

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

What is the price predicton of ARMP Stock?

What is Armata Pharmaceuticals Inc (ARMP)'s revenue for the last quarter?

Armata Pharmaceuticals Inc revenue for the last quarter amounts to 1.16M USD, decreased -61.02 % YoY.

What is Armata Pharmaceuticals Inc (ARMP)'s earnings per share (EPS) for the last quarter?

Armata Pharmaceuticals Inc. EPS for the last quarter amounts to -0.74 USD, increased 393.33 % YoY.

What changes have occurred in the market's expectations for Armata Pharmaceuticals Inc (ARMP)'s fundamentals?

How many employees does Armata Pharmaceuticals Inc (ARMP). have?

Armata Pharmaceuticals Inc (ARMP) has 60 emplpoyees as of January 09 2026.

What is Armata Pharmaceuticals Inc (ARMP) market cap?

Today ARMP has the market capitalization of 283.25M USD.